LONDON (ShareCast) - (Sharecast News) -

Sarepta Therapeutics's investigational gene therapy treatment SRP-9001 for Duchenne Muscular Dystrophy has received fast-track designation from America's Food and Drug Administration.

The therapy is designed to deliver the missing mycro-dystrophin encoding gene needed to produce the protein responsible for maintaining muscle tone.

Safety and tolerability data from a four patient trial at the one-year stage was recently reported on in JAMA Neurology.

Another study, which was randomized, double-blind, and placebo-controlled was ongoing with the results expected for early 2021.

Following a brief move higher, as of 1420 BST shares of Sarepta were drifting lower by 0.5% to $160.86.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE